NICE responds to Daily Mail cancer drug claims
pharmafile | April 12, 2010 | News story | Sales and Marketing | NICE, Sutent, election, off label
NICE has responded to a Daily Mail article on access to cancer drugs, in order to clear up claims of unfairness.
The article published on 9 April focused on the plight of Nikki Phelps, a patient with a rare glandular cancer, multiple endocrine neoplasia (MEN1).
Her consultant had recommended using Pfizer’s Sutent (sunitinib) as an off-label treatment for her condition, but funding has been refused by her Primary Care Trust.
The Daily Mail claimed NICE had played a role in blocking access to the patient, but NICE has now pointed out it has never been asked to review the drug for this cancer.
The report also claimed NICE had rejected 15 cancer treatments in the past 18 months and that “since then only five [cancer treatments] have been approved and ten rejected”.
In a letter written last week to Andrew Burnham, Andrew Lansley, Norman Lamb and Paul Dacre, Editor of the Mail, NICE chairman Sir Michael Rawlins responded that the Mail article was “factually inaccurate”.
Rawlins writes that in fact there have been ten recommendations with only four rejections and one ‘no appraisal’ (after Roche withdrew its Tarceva application).
The row takes on particular significance as it has arrived during the UK general election campaign.
NICE declared it would not be publishing any guidance during the election campaign in order to remain “politically neutral”.
Shadow health secretary Andrew Lansley was quoted in the article saying he believed was “unfair” on cancer patients. Opinion polls show that the NHS is the second most important issue to voters in the election, after the economy. The Conservatives have pledged to help cancer patients gain access to drug more easily than under Labour, promising to create a dedicated £200 million fund for new cancer treatments.
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
